Jerald P Radich
SWOG Cancer Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jerald P Radich as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05564390 · MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)National Cancer Institute (NCI) · recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 10 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT05564390
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:11 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- 2,731 citationsRCR 52.7
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.N Engl J Med · 20171,001 citationsRCR 32.5
- Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.N Engl J Med · 2003955 citationsRCR 17.4
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia · 2009694 citationsRCR 15.6
- 391 citationsRCR 9.0
- 308 citationsRCR 6.2
- 294 citationsRCR 8.0
- 244 citationsRCR 8.1
- 234 citationsRCR 6.0
- 227 citationsRCR 5.6